Recruitment remains a well-known hurdle in Phase 1 oncology clinical trials, but what happens after enrolment is equally vital: patient retention. Keeping patients o...

Drug development commonly encounters a bottleneck at the clinical trial stage. Patient recruitment is notoriously challenging, with many studies facing costly delays...

Cancer prevalence is rising globally. Radiopharmaceuticals and Theranostics offer precise, targeted diagnostic and therapeutic solutions for safer, more tolerable on...

As the European and overall worldwide regulation strives to become clearer, unambiguous, harmonised and as a result, more restrictive and demanding, this tendency st...

The Asia-Pacific (APAC) region has rapidly emerged as one of the most dynamic markets in global clinical development. Over the past decade, demand for innovative the...

As artificial intelligence (AI) gains prominence in drug development, regulatory agencies such as the US Food and Drug Administration (FDA) are creating and implemen...